Topography-guided LASIK enhancement advantageous
April 1st 2005Athens, Greece—Topography-guided LASIK enhancement using the Allegretto Wave system (WaveLight Laser Technologie AG, Erlangen, Germany) appears to be safe and effective for improving poor quality of vision associated with small, eccentric ablations and irregular astigmatism after previous refractive surgery, said A. John Kanellopoulos, MD.
Proper use of antibiotics essential for good outcomes
March 15th 2005Antibiotic resistance is a growing challenge, especially in ophthalmic surgery, and clinicians must remain vigilant and well informed to reduce the risk of infection in their patients, said Michael B. Raizman, MD, a cornea specialist with Ophthalmic Consultants of Boston.
Phakic IOL offers excellent outcomes for FDA cohort
March 15th 2005Atlanta—Up-to-date results from participants in the FDA clinical trial of the recently approved Verisyse phakic myopic IOL (Advanced Medical Optics) demonstrate that implant provides excellent refractive outcomes with a good safety profile, according to R. Doyle Stulting, MD, PhD.
PSTI, focal laser deemed safe for diabetic macular edema
March 15th 2005New Orleans—Posterior subtenon triamcinolone injection (PSTI) combined with focal laser improves the clinical outcome in diabetic macular edema (DME), according to results of a small, single-center, randomized prospective study, said Murat Tunc, MD, during the American Academy of Ophthalmology annual meeting.
TTT stabilizes vision in advanced AMD-related CNV
March 15th 2005Coronado, CA—Transpupillary thermotherapy (TTT) alone and combined with a single pretreatment intravitreal injection of triamcinolone acetonide 4 mg are similarly associated with vision stabilization over a 6-month follow-up period in eyes with large complicated choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), reported Jans Fromow-Guerra, MD, PhD, at the annual meeting of the American Society of Retinal Specialists.
Proper use of antibiotics essential for good outcomes
March 15th 2005Antibiotic resistance is a growing challenge, especially in ophthalmic surgery, and clinicians must remain vigilant and well informed to reduce the risk of infection in their patients, said Michael B. Raizman, MD, a cornea specialist with Ophthalmic Consultants of Boston.
Clinical performance supports role of phakic lens
March 15th 2005New Orleans—Results from continued follow-up of myopic eyes enrolled in the FDA clinical trial of the Verisyse phakic lens (Advanced Medical Optics) support the conclusion that the iris-fixated implant is a safe, effective, and very useful adjunct in a refractive surgery practice, said Richard L. Lindstrom, MD, at a session during the International Society of Refractive Surgery of the American Academy of Ophthalmology annual meeting.
Quality of life greatly improves after cataract surgery
March 15th 2005Jackson, MI—The patient-reported quality of life is high with the AcrySof IOLs (Alcon Laboratories), according to Paul Ernest, MD, who reported a significant improvement in the quality of life after cataract surgery with implantation of either a conventional AcrySof IOL or the AcrySof Natural lens.
Modified prolate anterior surface IOL improves acuity
March 15th 2005New Orleans—The modified prolate anterior surface IOL (Tecnis, AMO) is creating a new standard for visual performance after cataract surgery, according to Robert M. Kershner, MD, MS, FACS, at the Spotlight on Cataracts 2004: Cataract Controversies Symposium, held during the joint meeting of the American Academy of Ophthalmology and European Society of Ophthalmology.
Secondary IOLs in children remain controversial
March 15th 2005New Orleans—The condition of the anterior segment will determine the outcome of secondary IOL implantation in children, according to Edward G. Buckley, MD, chief, divisions of pediatrics and neuro-ophthalmology, Duke University Eye Center, Durham, NC.
Apodized diffractive IOL offers excellent solution for presbyopia
March 15th 2005New Orleans—Refractive lens exchange (RLE) with implantation of the Acrysof SA 60D3 ReSTOR IOL (Alcon Laboratories) is an effective method for treating myopia and hyperopia in presbyopic age patients, said Francesco Carones, MD, at the American Academy of Ophthalmology's refractive surgery subspecialty day meeting.
Aspheric IOL brings benefits of being aberration-free
March 15th 2005Brookville, PA—The new aberration-free aspheric IOL (SofPort Advanced Optics, Bausch & Lomb) is an exciting advance in implant technology because of its potential to offer better quality of vision to all patients, said Louis D. "Skip" Nichamin, MD.
Toric ICL promising for high myopia with astigmatism
March 15th 2005San Diego—With data available from up to 1 year of follow-up in an ongoing FDA multicenter clinical trial, the toric ICL (STAAR Surgical) is demonstrating favorable efficacy, safety, and predictability for the correction of myopic astigmatism, said Capt. Steven C. Schallhorn, MD.
CMS OKs pegaptanib reimbursement rate
March 15th 2005Washington, DC—The Centers for Medicare & Medicaid Services has announced that as of Jan. 1, 2005, the Medicare Part B allowable for pegaptanib sodium (Macugen, Eyetech Pharmaceuticals) is 106% of average sales price (ASP), or $1,054.70 per injection.
CK corrects hyperopia, astigmatism after laser surgery
March 15th 2005Newark, NJ—Conductive keratoplasty (CK) is a safe and effective procedure to treat patients with LASIK complications, an off-label application of the procedure, in whom an additional laser procedure is contraindicated, said Peter Hersh, MD.
Disclose retina risks of of intraocular refractive surgery
March 15th 2005New Orleans—Patients undergoing intraocular refractive surgery with either refractive lens exchange (RLE) or phakic intraocular lens implantation need to be informed that there is a lifelong risk of retinal detachment, said Kirk H. Packo, MD, at the refractive surgery subspecialty day at the American Academy of Ophthalmology annual meeting.
Allergic disease therapies key to patient quality of life
March 1st 2005Quality of life (QOL) has become an issue in every branch of medicine, including ophthalmology. From an economic perspective, loss of productivity contributes to the economic burden of a disease in the same manner as the shared costs of treatment.